ProMRI AFFIRM Study of the EVIA/ENTOVIS Pacemaker With Safio S Pacemaker Leads


This investigation is designed to demonstrate the clinical safety of the EVIA/ ENTOVIS pacemaker system when used under specific MRI conditions.

Full Title of Study: “Master Study for the MRI Compatibility of the EVIA/ENTOVIS Pacemaker in Combination With Safio S Pacemaker Lead”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 2013

Detailed Description

In the past, MR scans were always contraindicated for pacemaker patients. If particular prerequisites and conditions are fulfilled, MR scans can now be conducted on patients with BIOTRONIK's EVIA/ENTOVIS pacemakers in combination with the Safio S pacemaker leads, scheduled to be part of this clinical study. The specific MRI conditions for this investigation with the EVIA/ENTOVIS pacemaker family and Safio S pacemaker leads are defined in the study protocol


  • Procedure: Evia/Entovis pacemaker system under Magnetic Resonance Imaging (MRI) conditions
    • patients will undergo an MRI scan for 30 minutes.

Arms, Groups and Cohorts

  • Pacemaker therapy
    • Patients with an EVIA/ ENTOVIS pacemaker device. See inclusion and exclusion criteria.

Clinical Trial Outcome Measures

Primary Measures

  • Primary hypothesis 1: MRI and pacing system related Serious Adverse Device Effect (SADE) free rate
    • Time Frame: 3 months
    • MRI and pacing system related Serious Adverse Device Effect (SADE) Free-Rate is greater than 90%.
  • Primary hypotheses 2 and 3: pacing threshold rise (atrial and ventricular)
    • Time Frame: 1 month
    • The atrial or ventricular MRI induced pacing threshold rise is not larger than or equal to 0.5 V between Pre-MRI and 1-month follow-up
  • Primary hypothesis 4: P-wave sensing attenuation
    • Time Frame: 1 month
    • P-wave attenuation: P-wave amplitude decrease (between pre-MRI follow-up and 1-month follow-up) exceeding 50% or a P-wave amplitude at 1-month follow-up smaller or equal to 1.5 mV
  • Primary hypothesis 5: R-wave sensing attenuation
    • Time Frame: 1 month
    • R-wave attenuation: R-wave amplitude decrease (between pre-MRI follow-up and 1-month follow-up) exceeding 50% or a R-wave amplitude at 1-month follow-up smaller or equal to 5.0 mV.

Participating in This Clinical Trial

Inclusion Criteria

  • Pacemaker system consisting solely of the EVIA/ENTOVIS pacemaker and Safio S pacemaker leads – The pacemaker system has to be implanted, repositioned or exchanged at least 5 weeks prior to enrollment – Age more than 18 years – Understand the nature of the procedure – Able and willing to complete MRI testing – Able and willing to activate and use the Cardio Messenger – Give written informed consent – Able to complete all testing required by the clinical protocol – Ability to measure atrial and/or ventricular pacing threshold(s)* (at 0.4 ms) – All pacing thresholds do not exceed 2.0V @0.4ms. – Available for follow-up visit at the investigational site – Patient body height greater or equal to 140 cm – Pectoral implantation – The ascertained lead impedance is between 200 and 1500 Ohms. Exclusion Criteria:

  • No EVIA/ENTOVIS /Safio S pacemaker system implanted – Pacing threshold(s) (at 0.4 ms) and sensing amplitudes are not measurable – Meet one or more of the contraindications – Being pregnant – Have a life expectancy of less than three months – Cardiac surgery already scheduled in the next three months – Enrolled in another cardiac clinical investigation – Have other medical implants that may interact with MRI, e.g. abandoned pacemaker/ICD leads, lead extensions, other active medical devices, non-MRI compatible devices (e.g. mechanical tricuspid valve) – Have other metallic artifacts/components in body that may interact with MRI

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Biotronik SE & Co. KG
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Aldo Rinaldi, Dr., Principal Investigator, Cardiology Department, St Thomas’ Hospital Lambeth Palace Road London, SE1 7EH United Kingdom E-mail:

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.